1529 Treffer:
1.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
2.
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
3.
A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Urothelkarzinom der Harnblase (incl. Nierenbecken, Ureter)
Datum: 2026-05-09
4.
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
5.
Durchführung zusätzlicher kontrastmittelfreier MRT-Sequenzen bei der Prostata-MRT zur Bestimmung des diagnostischen Potentials von d(r)SIR-Bildern
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
6.
A Prospective Observational Study to Evaluate Real-world Clinical Outcomes and Characteristics of Patients With mCRPC Treated With Olaparib + Abiraterone
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
7.
MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castrat
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
8.
IMPULS-A: Implementierung eines Unterstützungsprogramms für Langzeitkrebsüberlebende im Alter
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
9.
Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumo
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09
10.
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hor
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-05-09